Product Information
LINEZOLID 100 MG/5 ML SUSP is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $2.7358 per ML under NDC 00054031950. Its NADAC has been published 111 times since Aug 21, 2024.
FDA first approved this application on Jun 3, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
100 mg/5mL
Manufacturer
Hikma Pharmaceuticals USA Inc.NDC
00054031950
Classification
Generic
Dosage Form
POWDER, FOR SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LINEZOLIDApproval Type
Generic (ANDA)
FDA Application
ANDA200068FDA Approved
6/3/2015
TE Code
AB
On Market Since
6/3/2015
Pharmacological Classes
Price Statistics
The NADAC for LINEZOLID 100 MG/5 ML SUSP has been published 111 times since Aug 21, 2024, and over the history we have for it it has risen 49.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.7358 per ML |
|---|---|
| All-time high | $2.7358 (Sep 30, 2026) |
| All-time low | $1.6969 (Nov 20, 2024) |
| 52-week high | $2.7358 |
| 52-week low | $2.1500 |
| Median price | $2.2119 |
| Average price | $2.2632 |
| Largest weekly change | +15.1% (Dec 18, 2024) |
| Weeks tracked | 111 |
| Tracking since | Aug 21, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the linezolid market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hikma Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
linezolid market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Oxazolidinone Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LINEZOLID 100 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for LINEZOLID 100 MG/5 ML SUSP, manufactured by Hikma Pharmaceuticals USA Inc., is $2.7358 per ML (NDC 00054031950), effective Sep 30, 2026.
How has the price of LINEZOLID 100 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for LINEZOLID 100 MG/5 ML SUSP has risen 49.8%. It has been tracked across 111 weekly CMS publications since Aug 21, 2024.
What are the highest and lowest recorded NADAC prices for LINEZOLID 100 MG/5 ML SUSP?
Since Aug 21, 2024, the NADAC for LINEZOLID 100 MG/5 ML SUSP has ranged from a low of $1.6969 (Nov 20, 2024) to a high of $2.7358 (Sep 30, 2026), with a median of $2.2119 per ML.
Are there cheaper alternatives to LINEZOLID 100 MG/5 ML SUSP?
No other NADAC-published product currently shares the active ingredient and strength of LINEZOLID 100 MG/5 ML SUSP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LINEZOLID 100 MG/5 ML SUSP?
LINEZOLID 100 MG/5 ML SUSP (NDC 00054031950) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.